Evidence map›Paper›PMID 34312765›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy.

Benjamin Ongnok, Thawatchai Khuanjing, Titikorn Chunchai, Patcharapong Pantiya, Sasiwan Kerdphoo, Busarin Arunsak, Wichwara Nawara, Thidarat Jaiwongkam, Nattayaporn Apaijai, Nipon Chattipakorn and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Benjamin OngnokCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Thawatchai KhuanjingCenter of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, 50200, Chiang Mai, Thailand.
Titikorn ChunchaiCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Patcharapong PantiyaCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Sasiwan KerdphooCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Busarin ArunsakCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Wichwara NawaraCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Thidarat JaiwongkamCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Nattayaporn ApaijaiCenter of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, 50200, Chiang Mai, Thailand.
Nipon ChattipakornCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand.
Siriporn C ChattipakornCardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neuroelectrophysiology Unit, Chiang Mai University, 50200, Chiang Mai, Thailand. siriporn.c@cmu.ac.th.ORCID http://orcid.org/0000-0003-1677-7052
Chiang Mai University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although doxorubicin (Dox) is an effective chemotherapy medication used extensively in the treatment of breast cancer, it frequently causes debilitating neurological deficits known as chemobrain. Donepezil (DPZ), an acetylcholinesterase inhibitor, provides therapeutic benefits in various neuropathological conditions. However, comprehensive mechanistic insights regarding the neuroprotection of DPZ on cognition and brain pathologies in a Dox-induced chemobrain model remain obscure. Here, we demonstrated that Dox-treated rats manifested conspicuous cognitive deficits and developed chemobrain pathologies as indicated by brain inflammatory and oxidative insults, glial activation, defective mitochondrial homeostasis, increased potential lesions associated with Alzheimer's disease, disrupted neurogenesis, loss of dendritic spines, and ultimately neuronal death through both apoptosis and necroptosis. Intervention with DPZ co-treatment completely restored cognitive function by attenuating these pathological conditions induced by DOX. We also confirmed that DPZ treatment does not affect the anti-cancer efficacy of Dox in breast cancer cells. Together, our findings suggest that DPZ treatment confers potential neuroprotection against Dox-induced chemobrain.

Indexed as

AnimalsAntibiotics, AntineoplasticChemotherapy-Related Cognitive ImpairmentCholinesterase InhibitorsDonepezilDoxorubicinFemaleHumansInflammation MediatorsMaleMCF-7 CellsNeuroprotective AgentsOxidative StressRatsRats, WistarTreatment OutcomeAntibiotics, AntineoplasticCholinesterase InhibitorsDonepezilDoxorubicinInflammation MediatorsNeuroprotective AgentsAcetylcholinesterase inhibitorChemobrainChemotherapyDonepezilDoxorubicinNeurotoxicity

Identifiers

PMID34312765
PMCPMC8608968
OpenAlexW3186223729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.